Risk Factors for Patients with Stage IVB Hepatocellular Carcinoma and Extension into the Heart: Prognostic and Therapeutic Implications
| Autor: | Chung Hwan Jun, Sung Bum Cho, Sang-Ho Kim, Da Woon Sim, Young Eun Joo, Hyun Soo Kim, Sung Kyu Choi, Min Woo Chung, Hyoung Ju Hong, Park Changhwan, Jong Sun Rew |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Sorafenib
Oncology Adult Male medicine.medical_specialty Carcinoma Hepatocellular Inferior vena cava right atrium Metastasis Heart Neoplasms Risk Factors Internal medicine medicine metastasis Humans Heart Atria Stage (cooking) Transcatheter arterial chemoembolization neoplasms Aged Retrospective Studies Gastroenterology & Hepatology business.industry Liver Neoplasms Palliative Care Cancer General Medicine hepatocellular carcinoma Middle Aged medicine.disease Prognosis digestive system diseases medicine.vein Hepatocellular carcinoma Concomitant Multivariate Analysis Active cancer treatment Original Article Female business medicine.drug |
| Zdroj: | Yonsei Medical Journal |
| ISSN: | 1976-2437 0513-5796 |
| Popis: | Purpose To evaluate the risk factors of hepatocellular carcinoma (HCC) extension into the right atrium (RA) and determine poor prognostic factors for HCC extension to the heart. Materials and Methods A total of 665 patients who were newly diagnosed with HCC were analyzed retrospectively from January 2004 to July 2012. The patients were divided into two groups: 33 patients with HCC extending into the RA and 632 HCC patients during the same period. The patients with HCC extending into the RA were subdivided into shorter survival group (3 (p=0.016, OR: 13.89) and active treatment (p=0.024, OR: 0.054) were associated with prognostic factors in patients HCC extending into the RA. Active treatment such as radiation (n=1), transcatheter arterial chemoembolization (TACE) (n=11), Sorafenib (n=1), and combined modalities (n=2) were performed. Conclusion Modified UICC stage higher than IVA, vascular invasion and multinodular tumor type are independent risk factors for HCC extending to the RA. Active treatment may prolong survival in patients HCC extending into the RA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|